Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY. Lin YT, et al. Among authors: wei yf. Eur J Cancer. 2021 Oct;156:1-11. doi: 10.1016/j.ejca.2021.06.043. Epub 2021 Aug 13. Eur J Cancer. 2021. PMID: 34392186 Free article.
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Nadal E, Horinouchi H, Shih JY, Nakagawa K, Reck M, Garon EB, Wei YF, Kollmeier J, Frimodt-Moller B, Barrett E, Lipkovich O, Visseren-Grul C, Novello S. Nadal E, et al. Among authors: wei yf. Drug Saf. 2022 Jan;45(1):45-64. doi: 10.1007/s40264-021-01127-2. Epub 2021 Dec 20. Drug Saf. 2022. PMID: 34928484 Free PMC article. Clinical Trial.
310 results